Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC

被引：57

作者：

Yang, Fang ^{[1
]}

Wen, Yalei ^{[1
]}

Wang, Chaofan ^{[1
]}

Zhou, Yuee ^{[1
]}

Zhou, Yang ^{[1
]}

Zhang, Zhi-Min ^{[1
]}

Liu, Tongzheng ^{[1
]}

Lu, Xiaoyun ^{[1
]}

机构：

[1] Jinan Univ, Coll Pharm, 601 Huangpu Ave West, Guangzhou 510632, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2022年 / 230卷

基金：

中国国家自然科学基金;

关键词：

KRAS(G12C); Reversible-covalent inhibitors; PROTAC; Anticancer; Warheads; PROTEIN-DEGRADATION; AMG; 510; KRAS; INHIBITORS; DISCOVERY; CANCER;

D O I：

10.1016/j.ejmech.2021.114088

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

KRAS is the most frequently mutated oncogene and plays a predominant role in driving initiation and progression of multiple cancers. Attempts to degrade the oncogene KRAS(G12C) with PROTAC strategy have been considered as an alternative strategy to combate cancers. However, the irreversible PROTACs may compromise the substoichiometric activity to decrease the potency. Herein, we report the development of YF135, the first reversible-covalent PROTAC capable of recruiting VHL mediated proteasomal degradation of KRAS(G12C). YF135 induces the rapid and sustained degradation of endogenous KRAS(G12C) and attenuates pERK signaling in H358 and H23 cells in a reversible manner. (C) 2022 Elsevier Masson SAS. All rights reserved.

引用

页数：13

共 32 条

[21] Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRASG12C, are associated with renal toxicity in the Sprague Dawley rat
Werner, Jonathan A.
Davies, Rhian
Wahlstrom, Jan
Dahal, Upendra P.
Jiang, Min
Stauber, Jonathan
David, Benjamin
Siska, William
Thomas, Barbara
Ishida, Katsu
Humphreys, W. Griffith
Lipford, J. Russell
Monticello, Thomas M.
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2021, 423
[22] TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC
Tammaccaro, Salvina Laura
Prigent, Philippe
Le Bail, Jean-Christophe
Dos-Santos, Odette
Dassencourt, Laurent
Eskandar, Myriam
Buzy, Armelle
Venier, Olivier
Guillemot, Jean-Claude
Veeranagouda, Yaligara
Didier, Michel
Spanakis, Emmanuel
Kanno, Tokuwa
Cesaroni, Matteo
Mathieu, Stephane
Canard, Luc
Casse, Alhassan
Windenberger, Fanny
Calvet, Loreley
Noblet, Laurence
Sidhu, Sukhvinder
Debussche, Laurent
Moll, Jurgen
Valtingojer, Iris
PHARMACEUTICALS, 2023, 16 (04)
[23] Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
Yuan, Minghua
Chu, Yanan
Duan, Yongtao
FRONTIERS IN CHEMISTRY, 2021, 9
[24] JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors
Lorthiois, Edwige
Gerspacher, Marc
Beyer, Kim S.
Vaupel, Andrea
Leblanc, Catherine
Stringer, Rowan
Weiss, Andreas
Wilcken, Rainer
Guthy, Daniel A.
Lingel, Andreas
Bomio-Confaglia, Claudio
Machauer, Rainer
Rigollier, Pascal
Ottl, Johannes
Arz, Dorothee
Bernet, Pascal
Desjonqueres, Gaelle
Dussauge, Solene
Kazic-Legueux, Malika
Lozac'h, Marie-Anne
Mura, Christophe
Sorge, Mickael
Todorov, Milen
Warin, Nicolas
Zink, Florence
Voshol, Hans
Zecri, Frederic J.
Sedrani, Richard C.
Ostermann, Nils
Brachmann, Saskia M.
Cotesta, Simona
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (24) : 16173 - 16203
[25] Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Fell, Jay B.
Fischer, John P.
Baer, Brian R.
Blake, James F.
Bouhana, Karyn
Briere, David M.
Brown, Karin D.
Burgess, Laurence E.
Burns, Aaron C.
Burkard, Michael R.
Chiang, Harrah
Chicarelli, Mark J.
Cook, Adam W.
Gaudino, John J.
Hallin, Jill
Hanson, Lauren
Hartley, Dylan P.
Hicken, Erik J.
Hingorani, Gary P.
Hinklin, Ronald J.
Mejia, Macedonio J.
Olson, Peter
Otten, Jennifer N.
Rhodes, Susan P.
Rodriguez, Martha E.
Savechenkov, Pavel
Smith, Darin J.
Sudhakar, Niranjan
Sullivan, Francis X.
Tang, Tony P.
Vigers, Guy P.
Wollenberg, Lance
Christensen, James G.
Marx, Matthew A.
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (13) : 6679 - 6693
[26] Sotorasib inhibits ubiquitination degradation of TXNIP and suppresses glucose metabolism in KRASG12C mutant bladder cancer
Zhang, Zhi-Rong
Liu, Min-Qi
Ji, Yang
Xiao, Di
Wang, Wei-Fan
Zhou, Xiao-Chen
Wang, Ling-Hui
Li, Duo
Zou, Hui
Yang, Xiao-Ping
AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (11):
[27] Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C
Weiss, Andreas
Lorthiois, Edwige
Barys, Louise
Beyer, Kim S.
Bomio-Confaglia, Claudio
Burks, Heather
Chen, Xueying
Cui, Xiaoming
de Kanter, Ruben
Dharmarajan, Lekshmi
Fedele, Carmine
Gerspacher, Marc
Guthy, Daniel Alexander
Head, Victoria
Jaeger, Ashley
Nunez, Eloisa Jimenez
Kearns, Jeffrey D.
Leblanc, Catherine
Maira, Sauveur-Michel
Murphy, Jason
Oakman, Helen
Ostermann, Nils
Ottl, Johannes
Rigollier, Pascal
Roman, Danielle
Schnell, Christian
Sedrani, Richard
Shimizu, Toshio
Stringer, Rowan
Vaupel, Andrea
Voshol, Hans
Wessels, Peter
Widmer, Toni
Wilcken, Rainer
Xu, Kun
Zecri, Frederic
Farago, Anna F.
Cotesta, Simona
Brachmann, Saskia M.
CANCER DISCOVERY, 2022, 12 (06) : 1500 - 1517
[28] Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C
Shin, Youngsook
Jeong, Joon Won
Wurz, Ryan P.
Achanta, Pragathi
Arvedson, Tara
Bartberger, Michael D.
Campuzano, Iain D. G.
Fucini, Ray
Hansen, Stig K.
Ingersoll, John
Iwig, Jeffrey S.
Lipford, J. Russell
Ma, Vu
Kopecky, David J.
McCarter, John
San Miguel, Tisha
Mohr, Christopher
Sabet, Sudi
Saiki, Anne Y.
Sawayama, Andrew
Sethofer, Steven
Tegley, Christopher M.
Volak, Laurie P.
Yang, Kevin
Lanman, Brian A.
Erlanson, Daniel A.
Cee, Victor J.
ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (09): : 1302 - 1308
[29] De Novo Rational design of peptide-based covalent inhibitors via mapping of complementary binding site residues – technical protocol and case study on KRASG12C and BTK481C
Ernest Oduro-Kwateng
Musab Ali
Ibrahim Oluwatobi Kehinde
Li Rao
Mahmoud E. S. Soliman
BMC Methods, 2 (1):
[30] First-in-Humans PET Imaging of KRASG12C Mutation Status in Non-Small Cell Lung and Colorectal Cancer Patients Using [18F]PFPMD
Li, Xiang
Ye, Jiajun
Wang, Jingyi
Quan, Zhiyong
Li, Guiyu
Ma, Wenhui
Zhang, Mingru
Yang, Weidong
Wang, Junling
Ma, Taoqi
Kang, Fei
Wang, Jing
JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (12) : 1880 - 1888

← 1 2 3 4 →